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elimination of B2M and protein bound retention solutes.
Given the inferior dialytic clearance of B2M and p-cresol
by peritoneal dialysis as compared to hemodialysis,
patients on peritoneal dialysis are more dependent on
residual renal function at least as far as the removal of
these retention solutes is concerned.3 Very recently, high
serum levels of both solutes were shown to be indepen-
dently associated with increased mortality.4,5 Undoubtedly
these observations will encourage nephrologists to broad-
en their view on adequacy beyond Kt/Vurea. All together,
these data moreover provide additional support for the
integrative care concept.6
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To the Editor: Collini et al.1 report two kidney graft
recipients with post-transplant lower limbs transient joint
pain. Bone scintigraphy and magnetic resonance (MR)
imaging of the symptomatic joints showed increased tracer
uptake and bone marrow edema, respectively. As already
suggested by others, they incriminate calcineurin-inhibitors
as the cause of this syndrome.
I do not believe that this hypothesis is warranted. Indeed,
identical symptoms have been described in kidney graft
recipients before the calcineurin-inhibitors era.2 The clinical
presentation best fits with the microtraumatic hypothesis we
initially proposed.3 Indeed, in multiple reports, MR imaging
consistently showed bone marrow edema and/or hemor-
rhage. The demonstration in some patients of bands of
hyposignal within areas of bone marrow edema further
supports the notion of impaction.3 In addition, Yamamoto
et al.4 recently showed in non-transplanted patients that
similar MR imaging lesions of symptomatic areas correspond
histologically to insufficiency fracture. Bone marrow infiltra-
tion with low intensity signal on T1-weighted MR image
corresponds histologically to viable bone and marrow tissue
with associated callus, edema, and vascular granulation.4
More interestingly, the presence in some T1-weighted MR
images of a focal band beneath the articular cartilage
corresponded to a fracture line and its associated repair
tissue.4
I suggest that a microfracture is the cause of this syndrome
and that inadapted physical activity level imposed on a
fragilized post-transplant bone could favor its occurrence.
The onset of the symptoms is thus unlikely to be prevented
by a reduction of calcineurin-inhibitors dose, in contrast to
the authors’ suggestion.
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Dr Goffin makes an interesting objection to the theory of
calcineurin-inhibitor-induced pain syndrome.1 We are
familiar with his hypothesis, which we were unfortunately
unable to deal with due to limits on the length of the paper.
It is true that there is no direct demonstration of the
existence of calcineurin-inhibitor-induced pain syndrome.
The hypothesis of microtraumas occurring in bone already
weakened by steroid therapy at high doses in the
immediate post-transplant period has its validity,2,3 and
it is possible that these repeated microtraumas in such a
delicate period could cause this syndrome. Moreover, this
agrees with the descriptions made before the calcineurin-
inhibitors era,4 with the cases described under therapy
with other types of drugs5 and with the recent comments
by Yamamoto et al.6
But the hypothesis of Grotz et al.7 is equally valid: in the
transplant patients affected by this syndrome there is, in
fact, no demonstration of the ‘insufficiency fractures’
which would be at the base of the alterations which are
found with the magnetic resonance imaging. In addition,
468 Kidney International (2007) 71, 466–470
l e t t e r t o t h e e d i t o r
the syndrome sometimes affects the joints and bones of the
upper limbs, which are more rarely subject to micro-
trauma, or at least more rarely subject to microtraumas,
which affect all of the joints contemporaneously. What is
more, the facts that therapy with non-steroidal anti-
inflammatory drugs has not been effective and that the
calcium channel blockers which likely reduce intraosseus
hypertension are successful in treating bone and joint
pain7,8 both support Grotz’s theory.
The two hypotheses therefore seem to be equally
plausible, and it is possible that it is a multifactorial
syndrome in which the drug-related intraosseus hyperten-
sion may be associated with repeated microtraumas. Only
a bone biopsy during the acute phase (ethically debatable)
could resolve the question.
What is clear is that it is not a reflex sympathetic
dystrophy syndrome as some authors still claim, but rather
that it is a syndrome in itself, which resolves spontaneously
and in which the use of non-steroidal anti-inflammatory
drugs is contraindicated.
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To the Editor: The renal community has recently enjoyed a
spirited reexamination of the role of angiotensin converting
enzyme inhibitors (ACEIs) in the treatment of chronic kidney
disease. The core renal concept of the effectiveness of ACEIs
has been challenged in Kidney International by Suissa et al.,1
several subsequent letters (Kidney Int, volume 70, October
2006), a previous meta-analysis, and results from the
ALLHAT study. These criticisms have elicited several vigorous
counter-responses.2,3
This debate appears to presume that ACEIs have been
optimally used, both in clinical studies and in the commu-
nity. If ACEIs can be prescribed in more effective manner,
there are implications for both viewpoints.
The defense of ACEIs is based on several carefully
performed large studies. Though convincing to many, it
should be noted that the statistically significant renal
protection demonstrated by either ACEIs or angiotensin 2
type 1 receptor blockers, as compared with controls, was
clinically modest. Twenty to forty per cent of treated patients
typically doubled their serum creatinine levels within
relatively short follow-up periods. Even supporters of
renin–angiotensin system (RAS) blockers must concede that
the mere prescription of an RAS blocker is an ineffective
therapy for too many patients.
However, it is possible that these modest results (or the
absence of any favorable result in other analyses) may derive
in part from the manner in which RAS blockers have been
prescribed. Brenner and others have recommended a
different approach to RAS blocker prescription, which was
subsequently termed ‘flexible and goal-oriented’ and re-
viewed in detail.4 This approach recognizes that lowering
blood pressure and urinary protein loss provides continually
increasing renal protection until the levels of B120 mm Hg
systolic (perhaps lower) and 300–500 mg proteinuria per day,
respectively. Therefore, the goal-oriented approach recom-
mends that both of these goals must be achieved in order to
presume optimal renal prognosis.
In no study of RAS blockers to date, have patients
consistently reached both goals. Clearly, more intensive RAS
blockade than previously prescribed is needed to reach these
stringent goals: multiple, complementary RAS blockers,
higher doses, and considerable effort. Moreover, interindivi-
dual variations in the ACEI insertion/deletion genotype, and
in other factors, make it unlikely that a single protocol or
approach will be broadly effective. Recognizing this, the goal-
oriented approach de-emphasizes broadly applied protocols.
Instead, it proposes a more flexible approach to RAS
blockade and hypertension that addresses interindividual
variations.
The evaluation of whether ACEIs (or RAS blockers in
general) are effective treatment for chronic kidney disease
should consider whether improved results might be obtained
with different strategies.
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